Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.32 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10752466 | 0.83 | BCL2 (0.38) | BCL2NPC1RAB9ACA12CA1 | |
| SCHEMBL21056503 | 0.81 | KDM4E (0.37) | BCL2NPC1RAB9AMAPK14CA12 | |
| SCHEMBL6840996 | 0.80 | BCL2 (0.36) | BCL2CA12CA1CA2CA7 | |
| SCHEMBL3786646 | 0.75 | BCL2 (0.40) | BCL2CA12CA1CA2CA7 | |
| SCHEMBL8896547 | 0.74 | PRSS1 (0.32) | BCL2 | |
| SCHEMBL5944757 | 0.72 | BCL2 (0.41) | BCL2CA12CA1CA2CA7 | |
| SCHEMBL1999459 | 0.72 | BCL2 (0.41) | BCL2RAB9ACA12CA1CA2 | |
| SCHEMBL5801902 | 0.72 | — | — | |
| SCHEMBL877569 | 0.71 | BCL2 (0.40) | BCL2CA12CA1CA2CA7 | |
| SCHEMBL10701753 | 0.71 | BCL2 (0.40) | BCL2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020155989-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF | 2002-10-24 | — | — | US | claimed |
| US-7115738-B2 | Hydroxyproline/phosphono oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF (US) | 2006-10-03 | — | — | US | disclosed |
| US-6962906-B2 | Oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1481085-A2 | OLIGONUCLEOTIDE ANALOGUES AND METHODS OF USE FOR MODULATING GENE EXPRESSION | Active Motif (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040014644-A1 | Oligonucleotide analogues and methods of use for modulating gene expression | ACTIVE MOTIF. | 2004-01-22 | — | — | US | disclosed |
| WO-2003068798-A2 | OLIGONUCLEOTIDE ANALOGUES AND METHODS OF USE FOR MODULATING GENE EXPRESSION | ACTIVE MOTIF (US) | 2003-08-21 | — | — | WO | disclosed |
| US-20030059789-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF | 2003-03-27 | — | — | US | disclosed |
| US-20020155989-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155989-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | HIRA, PHAX, SSU72 | BCL2 2192/4885NPC1 3503/4885RAB9A 4787/4885 |
| US-20040014644-A1 | Oligonucleotide analogues and methods of use for modulating gene expression | CRYAA, SRRT, HIRA | BCL2 1331/4885NPC1 3935/4885RAB9A 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.